Back to Directory
Oyster Therapeutics
Founded 2020
Oral targeted protein degraders for neurodegenerative diseases
Oyster Therapeutics, formerly Kesmalea Therapeutics, is a London-based biotechnology company developing small molecule targeted protein degraders for neurodegenerative diseases.
The company's proprietary SELFTAC platform is designed to enable bifunctional protein degraders to cross biological barriers as smaller components before assembling into active molecules.
Its lead programme focuses on developing an oral, brain-penetrant degrader targeting pathological tau associated with Alzheimer's disease and other tauopathies. In November 2026, Oyster raised $60 million in Series A-2 financing to advance its lead programme towards clinical development and support further development of the SELFTAC platform.
Company Notes
Previously Known As
Kesmalea Therapeutics